
According to data from Benzinga Pro, during Q1, LogicBio Therapeutics's (NASDAQ:LOGC) reported sales totaled $2.82 million. Despite a 26.49% increase in earnings, the company posted a loss of $6.66 million. LogicBio Therapeutics collected $2.03 million in revenue during Q4, but reported earnings showed a $9.06 million loss.